摘要
目的:探讨人脑胶质瘤组织中磷脂酰肌醇3′-激酶(PI3K)信号通路的关键信号分子激酶B(AKT)和雷帕霉素靶蛋白(mTOR)在人脑胶质瘤中的表达及意义。方法:收集45例胶质瘤患者的临床资料和病理诊断存档蜡块,同时收集同期25例其他非肿瘤病变的脑血管疾病患者的脑组织存档蜡块为对照组;采用免疫组织化学链霉菌抗生物素蛋白—过氧化物酶法(SP法)检测AKT及mTOR蛋白的表达,应用EXCEL、SPSS 25.0统计软件分析AKT及mTOR蛋白与胶质瘤患者临床病理特征的关系。结果:实验组脑组织细胞AKT及mTOR蛋白阳性表达率均高于对照组,差异有统计学意义(P<0.05);实验组AKT和mTOR存在显著正相关关系(r=0.448,P<0.01),不同性别、年龄、肿瘤发生部位及病理分级与AKT及mTOR蛋白阳性表达率之间比较,差异均无统计学意义(P>0.05)。结论:PI3K信号通路的关键信号分子AKT及mTOR在脑胶质瘤组织中存在过表达现象,但该表达与胶质瘤患者的临床病理特征无关。
Objective:To investigate the expression of key signaling molecular kinase B(AKT)and rapamycin target(mTOR)proteins in phosphatidylinositol 3'-kinase(PI3K)signaling pathway in human glioma tissues.Methods:Clinical data and pathological diagnosis of 45 patients with glioma were collected.At the same time,25 patients with other non-tumor cerebrovascular diseases were collected as control group.The expression of AKT and mTOR proteins was detected by the(SP)method of immunohistochemical streptomyces biotin-peroxidase.The relationship between AKT and mTOR proteins and clinicopathological features of glioma patients were analyzed by using EXCEL and SPSS 25.0 statistical software.Results:The expression rates of AKT and mTOR protein in brain tissue cells were higher than those in control group,and the difference was statistically significant(P<0.05).There was significant positive correlation between AKT and mTOR in experimental group(r=0.448,P<0.01).There was no significant difference in sex,age,tumor location,and the comparison of pathological grade,AKT,and expression rate of mTOR protein positive(P>0.05).Conclusion:The key signal molecular AKT and mTOR of PI3K signaling pathway are overexpressed in glioma tissue,but this expression is independent of clinicopathological characteristics of glioma patients.
作者
吴国敏
史珂蔓
刘娟
冯玲
杨宇石
李珀
徐澍
WU Guomin;SHI Keman;LIU Juan;FENG Ling;YANG Yushi;LI Po;XU Shu(Department of Oral Histopathology,School of Stomatology,Guizhou Medical University,Guiyang 550004,Guizhou,China;Department of Pathology,School of Clinical Medicine,Guizhou Medical University,Guiyang 550004,Guizhou,China)
出处
《贵州医科大学学报》
CAS
2020年第12期1422-1425,1432,共5页
Journal of Guizhou Medical University
基金
贵阳市科技局项目[筑科合(20161001)43]
贵州省科技厅联合资金项目[黔科合LH字(2016)7241]。
